A&P inks deal with Innovatix to expand specialty pharmacy business
NEW YORK — Grocer A&P, which operates more than 300 stores across six states, has signed a three-year agreement with Innovatix, whereby it will serve as A&P’s exclusive provider of specialty pharmacy services.
“We are pleased that A&P has joined our Specialty Pharmacy Management program,” stated Innovatix president and CEO John Sganga. “Innovatix is confident that its experience collaborating with key stakeholders in the specialty market, together with its ability to manage complex purchasing data, will prove valuable as A&P grows its specialty pharmacy business.”
Through Innovatix Specialty Pharmacy Management, a turnkey and à la carte solution for retail pharmacies to expand into the specialty market, A&P will receive access to specialty medications, as well as back office services including dispensing, data management, clinical and reimbursement support and patient financial assistance.
“We are very excited about our new partnership with Innovatix to provide comprehensive Specialty Medication service to our patients,” added Robin Page, VP pharmacy at A&P. “The expertise and resources that Innovatix offers will assist us with providing product as well as full medication therapy management support for our patients.”
Mylan, Banner settle cancer drug lawsuit with Eisai, Valeant
PITTSBURGH — Mylan and a partnering company will be able to sell a generic version of a cancer drug starting in summer 2015, under a court settlement announced Tuesday.
Mylan said that it and Banner Pharmacaps had reached a settlement agreement with Eisai and a subsidiary of Valeant Pharmaceuticals International to resolve a lawsuit filed over their generic version of Targretin (bexarotene) capsules in the 75-mg strength. The drug is used to treat certain forms of T-cell lymphoma.
Under the agreement, Mylan and Banner can start selling a generic version of Targretin starting in July 2015. Targretin in the 75-mg strength had sales of about $53.6 million during the 12-month period that ended in September, according to IMS Health.
NCPA: CMS policy change — pharmacies to affirmatively obtain consent from a beneficiary prior to shipping
ALEXANDRIA, Va. — Nearly 1,200 seniors have complained to Medicare this year about a litany of problems with mail-order pharmacies, including shipping unneeded medication and going without medication due to delayed shipments, the National Community Pharmacists Association noted Tuesday citing documentation recently released by the U.S. Centers for Medicare & Medicaid Services.
Starting Jan. 1, 2014, CMS will require Medicare Part D prescription drug plans to ensure that their contracted pharmacies affirmatively obtain consent from a beneficiary prior to shipping or delivering a new or refill prescription. The change comes in response to CMS receiving complaints from patients and cases documented by NCPA of individuals turning unused or expired medication into community pharmacies for disposal.
“We commend Medicare officials for acknowledging mail-order waste and for responding to the concerns of patients and community pharmacists by implementing this new policy,” stated NCPA CEO Douglas Hoey. “The complaints chronicled by CMS speak for many patients and underscore the fact that mail order is not for everyone. Patients deserve a choice to opt for the pharmacy provider that best meets their individual healthcare needs," he said.
“Community pharmacists often hear firsthand about patients’ unfortunate experiences with mail order,” Hoey added. “Most of these problems cited by seniors are avoidable in community pharmacies where a patient talks to a healthcare provider face-to-face. … Community pharmacists intervene so patients don’t go days or weeks without their medication.”